Tiansheng Shen
Biochemistry, Genetics and Molecular Biology · The Ohio State University
Publications
54
Citations
2,113
Est. group size
~1
Recurring co-author estimate
Active years
30
Publishing since 1995
Tiansheng Shen's work centers on the pathology of breast cancer, examining tumor markers, immune cell infiltration (such as PD-1/PD-L1 and CD4/CD8 T cells), and genetic mutations that help classify tumors and predict patient outcomes. Additional work has looked at diagnostic markers for distinguishing types of bone and cartilage tumors (sarcomas). This research relies on examining tissue samples and genetic data to improve cancer diagnosis and prognosis prediction.
Publication output has been irregular over the last decade, with active years (e.g., 2017, 2022) interspersed with gaps, and a low recent average of about 1.2 papers per year over the last five years.
Generated by claude-sonnet-5 from public bibliographic data · Jul 20, 2026
- Unusual staining of immunohistochemical markers PAX8 and CDX2 in breast carcinoma: a potential diagnostic pitfall
Human Pathology · 2022
- An Indoor positioning method based on Improved Elman neural network using sparrow search
2022 7th International Conference on Communication, Image and Signal Processing (CCISP) · 2022
- Abstract P4-10-30: PD-L1 expression in tumor infiltrating lymphocytes (TILs) inversely correlates with androgen receptor (AR) expression in HER2-positive breast cancer
Cancer Research · 2020
- The PD-1/PD-L1 Axis in HER2+ Ductal Carcinoma In Situ (DCIS) of the Breast
American Journal of Clinical Pathology · 2019
- The CD4/CD8 ratio of tumor-infiltrating lymphocytes at the tumor-host interface has prognostic value in triple-negative breast cancer
Human Pathology · 2017
- Diagnostic utility of IDH1/2 mutations to distinguish dedifferentiated chondrosarcoma from undifferentiated pleomorphic sarcoma of bone
Human Pathology · 2017
- Prognostic outcomes in advanced breast cancer: the metastasis-free interval is important
Human Pathology · 2017
- Diagnostic Utility of IDH1/2 Mutations to Distinguish Dedifferentiated Chondrosarcoma from Undifferentiated Pleomorphic Sarcoma of Bone
Author eBooks · 2017
- Corrigendum to “Diagnostic utility of IDH1/2 mutations to distinguish dedifferentiated chondrosarcoma from undifferentiated pleomorphic sarcoma of bone” [Hum Pathol 2017;65:239-46]
Human Pathology · 2017
- A microscopic landscape of the invasive breast cancer genome
Scientific Reports · 2016
- Prognostic Value of E-Cadherin and β-Catenin in Triple-Negative Breast Cancer
American Journal of Clinical Pathology · 2016
- <i>ERBB2</i> mutation is associated with a worse prognosis in patients with <i>CDH1</i> altered invasive lobular cancer of the breast
Oncotarget · 2016
- Clinicopathologic factors associated with de novo metastatic breast cancer
Pathology - Research and Practice · 2016
- Human Pathology×7
- Breast Cancer Research and Treatment×2
- American Journal of Clinical Pathology×2
- Scientific Reports×1
- Oncotarget×1
- Gary Tozbikian
Biochemistry, Genetics and Molecular Biology · The Ohio State University
- Mathew Cherian
Biochemistry, Genetics and Molecular Biology · The Ohio State University
- Ashley Pariser
Biochemistry, Genetics and Molecular Biology · The Ohio State University
- Bhuvaneswari Ramaswamy
Biochemistry, Genetics and Molecular Biology · The Ohio State University
- Sagar Sardesai
Biochemistry, Genetics and Molecular Biology · The Ohio State University
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 19, 2026.
Claim or correct this profile